Data as of Jun 18
| +0.18 / +1.42%|
The 6 analysts offering 12-month price forecasts for Endocyte Inc have a median target of 16.50, with a high estimate of 20.00 and a low estimate of 14.00. The median estimate represents a +28.11% increase from the last price of 12.88.
The current consensus among 7 polled investment analysts is to Buy stock in Endocyte Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.